Type 2 diabetes mellitus (T2DM) increases the risk of vascular cognitive impairment (VCI). It is unknown which type of vascular lesions and co-morbid etiologies, in particular Alzheimer’s disease pathology, are associated with T2DM in patients with VCI, and how this relates to cognition and prognosis.
Objective:
To compare brain MRI and cerebrospinal fluid (CSF) markers, cognition, and prognosis in patients with possible VCI with and without T2DM.
Methods:
We included 851 memory clinic patients with vascular brain injury on MRI (i.e., possible VCI) from a prospective cohort study (T2DM: n = 147, 68.4±7.9 years, 63% men; no T2DM: n = 704, 67.6±8.5 years, 52% men). At baseline, we assessed between-group differences in brain MRI abnormalities, CSF markers of Alzheimer’s disease, and cognitive profile. After two years follow-up, we compared occurrence of cognitive decline, stroke, and death.
Results:
The distribution of clinical diagnoses did not differ between patients with and without T2DM. T2DM patients had more pronounced brain atrophy (total and white matter volume), and more lacunar infarcts, whereas microbleeds were less common (all p < 0.05). CSF amyloid-β levels were similar between the groups. T2DM patients performed worse on working memory (effect size: – 0.17, p = 0.03) than those without, whereas performance on other domains was similar. During follow-up, risk of further cognitive decline was not increased in T2DM.∥Conclusion: In patients with possible VCI, presence of T2DM is related to more pronounced brain atrophy and a higher burden of lacunar infarcts, but T2DM does not have a major impact on cognitive profile or prognosis.∥
KoekkoekPS, KappelleLJ, van den BergE, RuttenGEHM, BiesselsGJ (2015) Cognitive function in patients with diabetes mellitus: Guidance for daily care. Lancet Neurol14, 329–340.
2.
BiesselsGJ, StrachanMWJ, VisserenFLJ, KappelleLJ, WhitmerRA (2014) Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions. Lancet Diabetes Endocrinol2, 246–255.
3.
GorelickPB, ScuteriA, BlackSE, DecarliC, GreenbergSM, IadecolaC, LaunerLJ, LaurentS, LopezOL, NyenhuisD, PetersenRC, SchneiderJA, TzourioC, ArnettDK, BennettDA, ChuiHC, HigashidaRT, LindquistR, NilssonPM, RomanGC, SellkeFW, SeshadriS (2011) Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke42, 2672–2713.
4.
MoranC, BeareR, PhanT, StarksteinS, BruceD, RominaM, SrikanthV (2017) Neuroimaging and its relevance to understanding pathways linking diabetes and cognitive dysfunction. J Alzheimers Dis59, 405–419.
AbnerEL, NelsonPT, KryscioRJ, SchmittFA, FardoDW, WoltjerRL, CairnsNJ, YuL, DodgeHH, XiongC, MasakiK, TyasSL, BennettDA, SchneiderJA, ArvanitakisZ (2016) Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology. Alzheimers Dement12, 882–889.
7.
BoomsmaJMF, ExaltoLG, BarkhofF, van den BergE, de BresserJ, HeinenR, KoekHL, PrinsND, ScheltensP, WeinsteinHC, van der FlierWM, BiesselsGJ (2017) Vascular cognitive impairment in a memory clinic population: Rationale and design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) study. JMIR Res Protoc6, e60.
8.
ChamberlainJJ, RhinehartAS, ShaeferCF, NeumanA (2016) Diagnosis and management of diabetes: Synopsis of the 2016 American diabetes association standards of medical care in diabetes. Ann Intern Med164, 542–552.
9.
WardlawJM, SmithEE, BiesselsGJ, CordonnierC, FazekasF, FrayneR, LindleyRI, O'BrienJT, BarkhofF, BenaventeOR, BlackSE, BrayneC, BretelerM, ChabriatH, DeCarliC, de LeeuwFE, DoubalF, DueringM, FoxNC, GreenbergS, HachinskiV, KilimannI, MokV, OostenbruggeR van, PantoniL, SpeckO, StephanBCM, TeipelS, ViswanathanA, WerringD, ChenC, SmithC, van BuchemM, NorrvingB, GorelickPB, DichgansM (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol12, 822–838.
10.
FazekasF, ChawlukJB, AlaviA, HurtigHI, ZimmermanRA (1987) MR signal abnormalities at 1.5-T in Alzheimer dementia and normal aging. Am J Roentgenol149, 351–356.
11.
SteenwijkMD, PouwelsPJW, DaamsM, Van DalenJW, CaanMWA, RichardE, BarkhofF, VrenkenH (2013) Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). Neuroimage Clin3, 462–469.
12.
Levy-CoopermanN, RamirezJ, LobaughNJ, BlackSE (2008) Misclassified tissue volumes in Alzheimer disease patients with white matter hyperintensities: Importance of lesion segmentation procedures for volumetric analysis. Stroke39, 1134–1141.
13.
BattagliniM, JenkinsonM, De StefanoN (2012) Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp33, 2062–2071.
14.
ChardDT, JacksonJS, MillerDH, Wheeler-KingshottCAM (2010) Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging32, 223–228.
15.
PopescuV, RanNCG, BarkhofF, ChardDT, Wheeler-KingshottCA, VrenkenH (2014) Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. Neuroimage Clin4, 366–373.
16.
ValverdeS, OliverA, LladoX (2014) A white matter lesion-filling approach to improve brain tissue volume measurements. Neuroimage Clin6, 86–92.
17.
ValverdeS, OliverA, RouraE, ParetoD, VilanovaJC, Ramió-TorrentáL, Sastre-GarrigaJ, MontalbanX, RoviraÁ, LladóX (2015) Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. Neuroimage Clin9, 640–647.
18.
KleinS, StaringM, MurphyK, ViergeverMA, PluimJ (2010) Elastix: A toolbox for intensity-based medical image registration. IEEE Trans Med Imaging29, 196–205.
19.
RitterF, BoskampT, HomeyerA, LaueH, SchwierM, LinkF (2011) Medical image analysis: A visual approach. IEEE Pulse2, 60–70.
20.
MulderC, VerweyNA, Van Der FlierWM, BouwmanFH, KokA, Van ElkEJ, ScheltensP, BlankensteinMA (2010) Amyloid-β(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem56, 248–253.
21.
FolsteinMF, FolsteinSE MP (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
22.
HughesCP, BergL, DanzigerWL, CobenLA (1982) A new clinical scale for the staging of dementia. Br J Psychiatry140, 566–572.
23.
MosesJ (1997) Neuropsychological information in the Wechsler adult intelligence scale —revised. Arch Clin Neu-ropsychol12, 97–109.
24.
van der ElstW, van BoxtelM, van BreukelenG (2005) Rey's verbal learning test: Normative data for 1855 healthy participants aged 24–81 years and the influence of age, sex, education, and mode of presentation. J Int Neuropsychol Soc11, 290–302.
25.
LindeboomJ (2002) Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry73, 126–133.
26.
CorriganJD, HinkeldeyNS (1987) Relationships between parts A and B of the Trail Making Test. J Clin Psychol43, 402–409.
27.
StroopJ (1935) Studies of interference in serial verbal reactions. J Exp Psych Gen121, 15–23.
28.
DeelmanBG, LiebrandWB, Koning-HaanstraM, van den BurgW (1980) Measurements of aphasic disorders. A brief description of the SAN-battery. Gerontologie11, 17–21.
29.
VerhageF (1964) Intelligence and age (in Dutch), v Gor-cum, Assen.
30.
(2000) Diagnostic and statistical manual of mental disorders: DSM-IV, American Psychiatric Association, Washington, DC.
31.
RomànGC, TatemichiTK, ErkinjunttiT, CummingsJL, MasdeuJC, GarciaJH, AmaducciL, OrgogozoJM, BrunA, HofmanA (1993) Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology43, 250–260.
32.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services TaskForce on Alzheimer's Disease. Neurology34,939–944.
33.
MckeithIG (2006) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology66, 1455.
WinbladB, PalmerK, KivipeltoM, JelicV, FratiglioniL, WahlundL-O, NordbergA, BackmanL, AlbertM, AlmkvistO, AraiH, BasunH, BlennowK, de LeonM, DeCarliC, ErkinjunttiT, GiacobiniE, GraffC, HardyJ, JackC, Jorma, RitchieK, van DuijnC, VisserP, PetersenRC (2004) Mild cognitive impairment—beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med256, 240–246.
36.
JessenF, AmariglioRE, Van BoxtelM, BretelerM, CeccaldiM, ChetelatG, DuboisB, DufouilC, EllisKA, Van Der FlierWM, GlodzikL, Van HartenAC, De LeonMJ, McHughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotinA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, De La SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement10, 844–852.
37.
CummingsJL, MegaM, GrayK, Rosenberg-ThompsonS, CarusiDA, GornbeinJ (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2308.
38.
DuitsFH, TeunissenCE, BouwmanFH, VisserPJ, Matts-sonN, ZetterbergH, BlennowK, HanssonO, MinthonL, AndreasenN, MarcussonJ, WallinA, RikkertMO, TsolakiM, ParnettiL, HerukkaSK, HampelH, De LeonMJ, SchröderJ, AarslandD, BlankensteinMA, ScheltensP, Van Der FlierWM (2014) The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?Alzheimers Dement10, 713–723.
39.
BiesselsGJ, KoffemanA, ScheltensP (2006) Diabetes and cognitive impairment: Clinical diagnosis and brain imaging in patients attending a memory clinic. J Neurol253, 477–482.
40.
BiesselsGJ, ReijmerYD (2014) Brain changes underlying cognitive dysfunction in diabetes: What can we learn from MRI?Diabetes63, 2244–2252.
MaF, WuT, MiaoR, Yu XiaoY, ZhangW, HuangG (2015) Conversion of mild cognitive impairment to dementia among subjects with diabetes: A population-based study of incidence and risk factors with five years of follow-up. J Alzheimers Dis43, 1441–1449.
52.
SolfrizziV, PanzaF, ColaciccoAM, D'IntronoA, CapursoC, TorresF, GrigolettoF, MaggiS, Del ParigiA, ReimanEM, CaselliRJ, ScafatoE, FarchiG, CapursoA (2004) Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology63, 1882–1891.
53.
BiesselsGJ, DespaF (2018) Cognitive decline and dementia in diabetes mellitus: Mechanisms and clinical implications. Nat Rev Endocrinol14, 591–604.
